Andrew is ranked in Tier 1 for mid-market M&A by both Chambers UK and legal 500 directories as well as being listed as one of The Lawyer's Hot 100. Andrew's clients describe him as 'a strong negotiator and problem solver' as well as 'fast and pragmatic and able to understand our needs very well'.

He has particular expertise in the Life Sciences sector and is recognised within the legal directories as a 'very talented' corporate and commercial lawyer with a long-standing commitment to the biotechnology and pharmaceutical industries. Andrew has a wealth of expertise in Indian and Russian M&A, having acted on some of the largest multi-billion dollar transactions to have taken place in those jurisdictions.

Whilst at his previous firm, Andrew led the team on the contested public takeover of his long-standing client Lavendon Group plc, a transaction which garnered industry recognition at The Legal Business Awards.

Show full CV Hide full CV

Latest news & insights

White microscope on yellow background
Life sciences & healthcare

Aspen Healthcare sold to Canadian-based property trust

27 September 2021

by Andrew McLean and Andrew Edge

Click here to find out more
Pipette adding sample to petri dish
Life sciences & healthcare

Advising Apollo Therapeutics on $145 million financing

21 June 2021

by Andrew Edge and Chris Cowley

Click here to find out more
Cloud Computing Servers
Corporate/M&A & capital markets

Taylor Wessing advises Databricks on acquisition of 8080 Labs

21 October 2021

by multiple authors

Click here to find out more
Businesswomen having meeting
Corporate/M&A & capital markets

Advising Current Health on Best Buy acquisition

21 October 2021

by Howard Palmer

Click here to find out more

Meet me at

There are no upcoming events